FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321822787> ?p ?o ?g. }

• W2321822787 endingPage "S38" @default.
• W2321822787 startingPage "S38" @default.
• W2321822787 abstract "Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), impairs patients' health-related quality of life (HRQoL). An ambitious goal of treatment is to achieve normalization of HRQoL. Anti-TNF agents are not only effective at inducing remission but have also been shown to improve HRQoL. The purpose of the present study was to determine the impact of 1 year of anti-TNF treatment on the HRQoL of IBD patients and to identify predictors of good to excellent HRQoL. A prospective, longitudinal study was performed on patients with Crohn's disease or ulcerative colitis treated with anti-TNF agents. Biological treatment was indicated for patients with refractory disease to corticosteroids or immunosuppressants and for patients with perianal fistula. Five patients had prior exposure to anti-TNF agents. The inflammatory bowel disease questionnaire (IBDQ) was used to measure the HRQoL at baseline and at weeks 14, 30, and 54. The Crohn's Disease Activity Index (CDAI) was used to assess the clinical response of CD patients. We considered patients in long-term clinical remission if the CDAI was less than 150 through week 54 from the start of biologic anti-TNF treatment. Mayo score was used to assess the clinical response of UC patients. Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point. Statistical Analysis: Variables were analyzed at 4 time points using variance analysis of repeated measurements (ANOVA) with the Tukey post-test. Logistic regression models were performed to identify predictors of good or excellent HRQoL. The study was approved by the local Research Ethics Committee and written informed consent was obtained from all subjects before inclusion. Thirty-five patients were included in this study. Seventy-seven percent of the patients had CD, and 23% had UC. Biologic anti-TNF treatment included adalimumab in 12 patients and infliximab in 23 patients. Forty-four percent of the CD patients had perianal disease. Clinical response was achieved in 24 patients (18 with CD and 6 with UC, P = 1.0). There was no association between clinical response and the following variables: age (P = 0.28), gender (P = 0.09), disease duration (P = 0.08), smoking status (P = 0.73) and biologic anti-TNF treatment (infliximab/adalimumab, P = 1.0). There was an association between clinical response and surgery (P = 0.001). All patients who achieved clinical response during follow-up also showed improved HRQoL. Gender female (OR: 0.038; 95% CI: 0.003–0.446; P = 0.009), depression (OR: 0.024; 95% CI: 0.002–0.317; P = 0.004) and without clinical response (OR: 0.053; 95% CI: 0.005–0.596; P = 0.017) were associated with good/excellent HRQoL. Clinical response to anti-TNF agents is associated with improvement in HRQoL in IBD patients. Predictors of good or excellent HRQoL were gender male, absence of depression and without clinical response." @default.
• W2321822787 created "2016-06-24" @default.
• W2321822787 creator A5008955702 @default.
• W2321822787 creator A5013244630 @default.
• W2321822787 creator A5013716099 @default.
• W2321822787 creator A5014353695 @default.
• W2321822787 creator A5030005645 @default.
• W2321822787 creator A5032256842 @default.
• W2321822787 creator A5040350814 @default.
• W2321822787 creator A5041181847 @default.
• W2321822787 creator A5054898820 @default.
• W2321822787 creator A5071856703 @default.
• W2321822787 creator A5072210539 @default.
• W2321822787 creator A5003588916 @default.
• W2321822787 date "2016-03-01" @default.
• W2321822787 modified "2023-10-02" @default.
• W2321822787 title "P-091 YI Predictors of Health-Related Quality of Life in Patients with Inflammatory Bowel Disease After 1 Year with Anti-TNF Agents" @default.
• W2321822787 doi "https://doi.org/10.1097/01.mib.0000480196.02515.05" @default.
• W2321822787 hasPublicationYear "2016" @default.
• W2321822787 type Work @default.
• W2321822787 sameAs 2321822787 @default.
• W2321822787 citedByCount "0" @default.
• W2321822787 crossrefType "journal-article" @default.
• W2321822787 hasAuthorship W2321822787A5003588916 @default.
• W2321822787 hasAuthorship W2321822787A5008955702 @default.
• W2321822787 hasAuthorship W2321822787A5013244630 @default.
• W2321822787 hasAuthorship W2321822787A5013716099 @default.
• W2321822787 hasAuthorship W2321822787A5014353695 @default.
• W2321822787 hasAuthorship W2321822787A5030005645 @default.
• W2321822787 hasAuthorship W2321822787A5032256842 @default.
• W2321822787 hasAuthorship W2321822787A5040350814 @default.
• W2321822787 hasAuthorship W2321822787A5041181847 @default.
• W2321822787 hasAuthorship W2321822787A5054898820 @default.
• W2321822787 hasAuthorship W2321822787A5071856703 @default.
• W2321822787 hasAuthorship W2321822787A5072210539 @default.
• W2321822787 hasBestOaLocation W23218227871 @default.
• W2321822787 hasConcept C102959455 @default.
• W2321822787 hasConcept C105795698 @default.
• W2321822787 hasConcept C126322002 @default.
• W2321822787 hasConcept C151956035 @default.
• W2321822787 hasConcept C159110408 @default.
• W2321822787 hasConcept C1862650 @default.
• W2321822787 hasConcept C2775862500 @default.
• W2321822787 hasConcept C2777138892 @default.
• W2321822787 hasConcept C2778260677 @default.
• W2321822787 hasConcept C2779134260 @default.
• W2321822787 hasConcept C2779280984 @default.
• W2321822787 hasConcept C2779951463 @default.
• W2321822787 hasConcept C2780479503 @default.
• W2321822787 hasConcept C33923547 @default.
• W2321822787 hasConcept C71924100 @default.
• W2321822787 hasConcept C90924648 @default.
• W2321822787 hasConcept C99476002 @default.
• W2321822787 hasConceptScore W2321822787C102959455 @default.
• W2321822787 hasConceptScore W2321822787C105795698 @default.
• W2321822787 hasConceptScore W2321822787C126322002 @default.
• W2321822787 hasConceptScore W2321822787C151956035 @default.
• W2321822787 hasConceptScore W2321822787C159110408 @default.
• W2321822787 hasConceptScore W2321822787C1862650 @default.
• W2321822787 hasConceptScore W2321822787C2775862500 @default.
• W2321822787 hasConceptScore W2321822787C2777138892 @default.
• W2321822787 hasConceptScore W2321822787C2778260677 @default.
• W2321822787 hasConceptScore W2321822787C2779134260 @default.
• W2321822787 hasConceptScore W2321822787C2779280984 @default.
• W2321822787 hasConceptScore W2321822787C2779951463 @default.
• W2321822787 hasConceptScore W2321822787C2780479503 @default.
• W2321822787 hasConceptScore W2321822787C33923547 @default.
• W2321822787 hasConceptScore W2321822787C71924100 @default.
• W2321822787 hasConceptScore W2321822787C90924648 @default.
• W2321822787 hasConceptScore W2321822787C99476002 @default.
• W2321822787 hasLocation W23218227871 @default.
• W2321822787 hasOpenAccess W2321822787 @default.
• W2321822787 hasPrimaryLocation W23218227871 @default.
• W2321822787 hasRelatedWork W1576589857 @default.
• W2321822787 hasRelatedWork W2021359433 @default.
• W2321822787 hasRelatedWork W2106015740 @default.
• W2321822787 hasRelatedWork W2739248189 @default.
• W2321822787 hasRelatedWork W2912638322 @default.
• W2321822787 hasRelatedWork W3022383156 @default.
• W2321822787 hasRelatedWork W3205942131 @default.
• W2321822787 hasRelatedWork W4226137497 @default.
• W2321822787 hasRelatedWork W52633626 @default.
• W2321822787 hasRelatedWork W79702259 @default.
• W2321822787 hasVolume "22" @default.
• W2321822787 isParatext "false" @default.
• W2321822787 isRetracted "false" @default.
• W2321822787 magId "2321822787" @default.
• W2321822787 workType "article" @default.